ReviewProbiotics and antimicrobial proteins2026
A Microbial Odyssey: Reshaping Probiotic Destinies through Advanced Delivery Technologies.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics have attracted considerable attention in recent years due to their potential in modulating the gut microbiota, enhancing immune function, and contributing to the management of metabolic disorders, inflammatory diseases, and neuropsychiatric conditions. However, their clinical efficacy is often compromised by harsh gastrointestinal conditions such as gastric acid, bile salts, and digestive enzymes that significantly reduce probiotic viability. Moreover, current formulations face challenges in terms of bioavailability, targeted delivery, and consistency of therapeutic outcomes. To address these limitations, a variety of delivery strategies have been developed, including colon- and inflammation-targeted systems, genetically engineered and surface-modified probiotics, microencapsulation technologies with material innovations and functional enhancements, as well as inorganic and organic nanocarrier platforms. In parallel, interdisciplinary approaches such as smart-responsive systems, biomimetic technologies, microbiota remodeling, and synthetic biology have been increasingly employed to achieve precise release and sustained colonization in the host. This review systematically summarizes recent advances in probiotic delivery technologies, covering diverse engineering strategies and material platforms. It also critically examines key challenges in clinical translation, including formulation stability, inter-individual variability, regulatory inconsistencies, and long-term safety concerns, aiming to provide a comprehensive reference for the optimization and high-quality development of probiotic delivery systems. Aiming to provide a comprehensive reference and a forward-looking framework to guide the rational design of next-generation probiotic biotherapeutics.
Indexed as
Identifiers
41591587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.